insights_auto
Why is LCTX down 5,73%?
Dive Deeperchevron_right
LCTX:NYSEAMERICAN
Lineage Cell Therapeutics Inc
US$0,97
arrow_downward
-5,73%(-0,059) 1D
US$0,97
0,00% (0,00)
bedtimeAfter hours
Closed: 28 ກ.ຍ., 16 ໂມງ 0 ນາທີ 00 ວິນາທີ GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for LCTX...
Open
US$1,02
High
US$1,04
Low
US$0,96
Mkt. cap
245,57 ລ້ານ
Avg. vol.
1,22 ລ້ານ
Volume
0,00
52-wk high
US$2,09
52-wk low
US$0,91
EPS
US$-0,14
Beta
1,54
Shares outstanding
252,91 ລ້ານ
No. of employees
75
Open
US$1,02
High
US$1,04
Low
US$0,96
Mkt. cap
245,57 ລ້ານ
Avg. vol.
1,22 ລ້ານ
Volume
0,00
52-wk high
US$2,09
52-wk low
US$0,91
EPS
US$-0,14
Beta
1,54
Shares outstanding
252,91 ລ້ານ
No. of employees
75
News stories
From web sources and news partners
Timothy Sykes
·
2 ມື້ກ່ອນ
LCTX Jumps As Lineage Wins Long-Dated AlloSCOPE Patent
https://www.dars.gov.et/
·
1 ເດືອນກ່ອນ
Lineage Cell Therapeutics (LCTX) Holds Above $1.07 Support as Biotech Consolidates - Opening Range Breakout
Profile
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs. Lineage’s programs are based on its robust proprietary cell-based therapy platform and associated in-house development and manufacturing capabilities. With this platform, Lineage develops and manufactures specialized, terminally differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed to either replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury or administered as a means of helping the body mount an effective immune response to cancer. Wikipedia
About Lineage Cell Therapeutics Inc